Entacapone functions as a catechol-O-methyltransferase inhibitor for Parkinson's disease. This mechanism modulates neurological processing by preventing the breakdown of levodopa, extending its systemic activity.
Targeting the breakdown of dopamine, entacapone belongs to the catechol-O-methyltransferase (COMT) inhibitor class. The compound extends the action of levodopa by preventing its rapid conversion to inactive metabolites. It appears as the active ingredient in fixed-dose combinations such as Stalevo, which also contain levodopa and carbidopa. Clinically, it is used to improve motor control in people living with Parkinson’s disease.
Incorporated into tablets marketed as Stalevo, this molecule is delivered together with levodopa and carbidopa in a single pill. The tablets are manufactured in standard immediate-release forms for oral use, aligning with Singapore’s Medicines Registration guidelines. Both generic and brand-name options are available, but all must meet the Health Sciences Authority’s quality standards before reaching patients.
Helping patients with fluctuating motor control, the agent is employed in several Parkinson’s disease scenarios. It assists individuals who experience “wearing-off” periods where medication effects diminish before the next dose. The compound is also considered for patients whose response to levodopa alone becomes unpredictable over time. Typically, adults diagnosed with idiopathic Parkinson’s disease are the primary users.
By slowing the enzymatic conversion of levodopa, it prolongs dopamine availability in the brain’s synaptic spaces. The result is a steadier stimulation of dopamine receptors, which can reduce the frequency of sudden motor lapses. This action complements carbidopa, which blocks peripheral breakdown of levodopa, allowing more of the precursor to reach the central nervous system.
Mild nausea, occasional dizziness, and transient headache may occur during the first weeks of therapy. These effects usually lessen as the body adjusts to the medication.
Rarely, patients report severe liver enzyme elevations, allergic skin eruptions, or sudden changes in blood pressure. Prompt medical evaluation is advised if such signs arise.
The substance should be avoided in individuals with known hypersensitivity to COMT inhibitors, active liver disease, or severe renal impairment. Use during pregnancy and breastfeeding requires careful risk assessment by a qualified professional.
Alcohol consumption can intensify dizziness and hypotension, while certain antidepressants and antihypertensive agents may modify its effectiveness. For precise interaction details, refer to the specific medication’s official insert.
Storing the tablets in a cool, dry place protects their stability; exposure to high humidity or temperature fluctuations should be avoided. Treatment duration varies: some patients use the combination for short-term symptom smoothing, while others remain on it chronically to manage long-term disease progression. For detailed usage, dosing, and administration, refer to the specific medication’s clinical information.
This educational overview of entacapone is not medical advice; individual medicines such as Stalevo differ in strength, formulation, and instructions. The author disclaims liability for any clinical application of the information provided. Patients are advised to consult their specific medication labeling and a licensed healthcare professional for personalized guidance.
